Back to top
more

Premier (PINC)

(Real Time Quote from BATS)

$19.75 USD

19.75
516,616

-0.04 (-0.20%)

Updated Aug 28, 2024 03:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Premier (PINC) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Premier (PINC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Premier, Inc. (PINC) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Premier (PINC) delivered earnings and revenue surprises of 40.82% and 12.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Premier (PINC) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Premier (PINC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

ReWalk Robotics (LFWD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ReWalk (LFWD) delivered earnings and revenue surprises of 5.66% and 0.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

The Oncology Institute, Inc. (TOI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

The Oncology Institute (TOI) delivered earnings and revenue surprises of -70% and 4.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 10% and 69.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sharecare, Inc. (SHCR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sharecare (SHCR) delivered earnings and revenue surprises of -33.33% and 4.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CoDiagnostics (CODX) delivered earnings and revenue surprises of 26.47% and 564.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Meets Q2 Earnings Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of 0% and 3.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Bausch + Lomb (BLCO) Matches Q2 Earnings Estimates

by Zacks Equity Research

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of 0% and 4.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Alignment Healthcare (ALHC) Surges 11.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Alignment Healthcare (ALHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Here's What Key Metrics Tell Us About Premier (PINC) Q3 Earnings

by Zacks Equity Research

Although the revenue and EPS for Premier (PINC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Premier, Inc. (PINC) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Premier (PINC) delivered earnings and revenue surprises of 17.02% and 9.48%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Premier (PINC) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Evaluate the expected performance of Premier (PINC) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

ModivCare (MODV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ModivCare (MODV) delivered earnings and revenue surprises of -145% and 2.73%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) Stock Jumps 4.1%: Will It Continue to Soar?

by Zacks Equity Research

Revvity (RVTY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Compared to Estimates, Premier, Inc. (PINC) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Premier, Inc. (PINC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Premier, Inc. (PINC) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 11.11% and 1.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Signs Peripheral Access Purchasing Deal With PINC

by Zacks Equity Research

Teleflex (TFX) secures the Peripheral Access purchasing agreement with Premier, Inc.

Compared to Estimates, Premier, Inc. (PINC) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Premier, Inc. (PINC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Strength Seen in Establishment Labs Holdings Inc. (ESTA): Can Its 14.3% Jump Turn into More Strength?

by Zacks Equity Research

Establishment Labs Holdings Inc. (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Compared to Estimates, Premier, Inc. (PINC) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Premier, Inc. (PINC) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Premier, Inc. (PINC) Tops Q4 Earnings Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.49% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

UpHealth, Inc. (UPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

UpHealth, Inc. (UPH) delivered earnings and revenue surprises of 13.04% and 18.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 0% and 29.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?